Free Newsletter
AZ bids for yet another Seroquel use
AstraZeneca is taking its Seroquel-broadening mission further into Europe with an application to market the atypical antipsychotic for generalized anxiety disorder. If European regulators approve the new use, Seroquel would be the first med in its class OK'd for anxiety.
The company says it's basing its application on five Phase III studies encompassing more than 3,500 patients. The data, presented at the American Psychiatric Association confab in May, showed "significantly greater symptom improvements" in the Seroquel patients versus those on placebo, the company said.
AstraZeneca is awaiting an FDA decision on using Seroquel to treat short-term anxiety and for long-term maintenance of the disorder. The company also has an application for major depressive disorder pending, both in the U.S. and in Europe.
- see the AstraZeneca release
Related Articles:
AZ stock leaps on Seroquel hearing news
Seroquel researcher got cash from AZ
AZ takes steps to shore up Seroquel
AZ's Seroquel receives additional approval
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: